No Data
Biogen Bid to Revive Tecfidera Patents Denied by U.S. Supreme Court
Biogen (NASDAQ:BIIB) failed to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera on Monday after the U.S. Supreme Court declined to hear a case in a legal di
Merck Says Appeals Court Rules in Company's Favor on Sitagliptin Patent
Merck Wins Appeals Court Ruling Against Viatris Over Generic Diabetic Drugs
Merck (NYSE:MRK) announced Thursday that the federal appeals court handed it a favorable ruling in a patent dispute with Viatris (NASDAQ:VTRS) over the generic drugmaker's attempt to market copycat ve
EU Generic Drugmakers Flag Risks to Production Due to Rising Costs
A lobby group representing the generic drugmakers in Europe has pointed out that the cost inflation, rising energy costs, and price control policies have made manufacturing in the region unsustainable
Aquestive Adds 20% as Epinephrine Sublingual Film Outperforms Autoinjector
Aquestive Therapeutics, Inc. (NASDAQ:AQST) gained ~20% pre-market Tuesday after the company announced that its AQST-109 epinephrine sublingual film compared favorably to other forms of epinephrine tre
Healthcare Outperforms S&P 500 as Large Cap Pharma Rebounds
Healthcare stocks led the gainers in the S&P 500 on Thursday, as large-cap pharma stocks witnessed a resurgence a day after the U.S. Federal Reserve approved its third consecutive interest-rate in
Trending: Merck Reports Court Win in Diabetes Patent Lawsuit Against Viatris
1511 ET -- Merck & Co. is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Earlier Thursday, Merck said a West Virginia dis
Viatris Faces Legal Setback to Market Generics for Merck’s Diabetic Drugs
Merck (NYSE:MRK) has dealt a blow to Viatris' (VTRS) efforts to bring generic versions of its blockbuster drugs Januvia and Janumet after a favorable court ruling in a patent lawsuit regarding sitagli
Merck Granted Favorable Rule in Sitagliptin Patent Lawsuit Against Viatris
Merck: Agreements Allow Cos to Bring Generic Versions of JANUMET XR to Market in July 2026 or Earlier Under Certain Circumstances
Loading...
